Loading…
Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity
1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activi...
Saved in:
Published in: | Journal of pharmaceutical sciences 1980-10, Vol.69 (10), p.1198-1202 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43 |
---|---|
cites | cdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43 |
container_end_page | 1202 |
container_issue | 10 |
container_start_page | 1198 |
container_title | Journal of pharmaceutical sciences |
container_volume | 69 |
creator | Ellis, K.O. Wessels, F.L. Burns, R.H. Pong, S.F. |
description | 1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects. |
doi_str_mv | 10.1002/jps.2600691021 |
format | article |
fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jps_2600691021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915434215</els_id><sourcerecordid>JPS2600691021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</originalsourceid><addsrcrecordid>eNqFkM1vFCEYh4nR1LV69WYyxzZZtjB8DHO0jbY1TW2ixiNh4R2XOjtMgG473v2_xU5T48F44SX8PsL7IPSakhUlpD66HtOqloTIlpKaPkELKmqCJaHNU7Qohhozwdvn6EVK16TYiBB7aE9SIhtKF-jn1cbErbGhD9-mKnQVxQdsybHzdtOHGNYw_Jj6Q1zelmIpcYYczWZyMeD6gJ4d4nGKfutdGGBZmWoIO-grM2TvYIyQUrlWNmzHcDO46tbnzb1ohjsPeaqMzX7n8_QSPetMn-DVw9xHX96_-3xyhi8-np6fvL3AlvGaYt5ZYzgRresasWYclAKmuFGNFJTZTpm6tYzyVqi1soTxchhnTA2ENcxyto9Wc6-NIaUInR7L702cNCX6N05dcOo_OEvgzRwYb9ZbcI_2B35Fb2f91vcw_adNf7j69Fc3nrM-Zbh7zJr4XcuGNUJ_vTzV7TFVihCmZfGr2Q-F0M5D1Ml6GCw4H8Fm7YL_1xq_ALmlooA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</title><source>Wiley-Blackwell Journals</source><creator>Ellis, K.O. ; Wessels, F.L. ; Burns, R.H. ; Pong, S.F.</creator><creatorcontrib>Ellis, K.O. ; Wessels, F.L. ; Burns, R.H. ; Pong, S.F.</creatorcontrib><description>1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.2600691021</identifier><identifier>PMID: 6106711</identifier><language>eng</language><publisher>Washington: Elsevier Inc</publisher><subject>1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo ; 4-Dichlorobenzyl) - 3 ; 6-tetrahydro-2(1H)-pyrimidone ; 6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity ; Animals ; Anti-Anxiety Agents ; Antidepressive Agents ; Brain Chemistry - drug effects ; Cats ; CNS activity-1- ; CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo ; evaluation of antidepressant and antianxiety activity ; Female ; Histamine H1 Antagonists ; Humans ; in vitro and in vivo ; Lethal Dose 50 ; Male ; Mice ; Monoamine Oxidase Inhibitors ; Neurotransmitter Agents - metabolism ; Nictitating Membrane - drug effects ; Parasympatholytics ; Pentylenetetrazole - antagonists & inhibitors ; Pyrimidinones - pharmacology ; Rats ; Stereotyped Behavior - drug effects ; Tetrabenazine - antagonists & inhibitors</subject><ispartof>Journal of pharmaceutical sciences, 1980-10, Vol.69 (10), p.1198-1202</ispartof><rights>1980 Wiley-Liss, Inc., A Wiley Company</rights><rights>Copyright © 1980 Wiley‐Liss, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</citedby><cites>FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.2600691021$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.2600691021$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6106711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ellis, K.O.</creatorcontrib><creatorcontrib>Wessels, F.L.</creatorcontrib><creatorcontrib>Burns, R.H.</creatorcontrib><creatorcontrib>Pong, S.F.</creatorcontrib><title>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.</description><subject>1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo</subject><subject>4-Dichlorobenzyl) - 3</subject><subject>6-tetrahydro-2(1H)-pyrimidone</subject><subject>6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity</subject><subject>Animals</subject><subject>Anti-Anxiety Agents</subject><subject>Antidepressive Agents</subject><subject>Brain Chemistry - drug effects</subject><subject>Cats</subject><subject>CNS activity-1-</subject><subject>CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo</subject><subject>evaluation of antidepressant and antianxiety activity</subject><subject>Female</subject><subject>Histamine H1 Antagonists</subject><subject>Humans</subject><subject>in vitro and in vivo</subject><subject>Lethal Dose 50</subject><subject>Male</subject><subject>Mice</subject><subject>Monoamine Oxidase Inhibitors</subject><subject>Neurotransmitter Agents - metabolism</subject><subject>Nictitating Membrane - drug effects</subject><subject>Parasympatholytics</subject><subject>Pentylenetetrazole - antagonists & inhibitors</subject><subject>Pyrimidinones - pharmacology</subject><subject>Rats</subject><subject>Stereotyped Behavior - drug effects</subject><subject>Tetrabenazine - antagonists & inhibitors</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><recordid>eNqFkM1vFCEYh4nR1LV69WYyxzZZtjB8DHO0jbY1TW2ixiNh4R2XOjtMgG473v2_xU5T48F44SX8PsL7IPSakhUlpD66HtOqloTIlpKaPkELKmqCJaHNU7Qohhozwdvn6EVK16TYiBB7aE9SIhtKF-jn1cbErbGhD9-mKnQVxQdsybHzdtOHGNYw_Jj6Q1zelmIpcYYczWZyMeD6gJ4d4nGKfutdGGBZmWoIO-grM2TvYIyQUrlWNmzHcDO46tbnzb1ohjsPeaqMzX7n8_QSPetMn-DVw9xHX96_-3xyhi8-np6fvL3AlvGaYt5ZYzgRresasWYclAKmuFGNFJTZTpm6tYzyVqi1soTxchhnTA2ENcxyto9Wc6-NIaUInR7L702cNCX6N05dcOo_OEvgzRwYb9ZbcI_2B35Fb2f91vcw_adNf7j69Fc3nrM-Zbh7zJr4XcuGNUJ_vTzV7TFVihCmZfGr2Q-F0M5D1Ml6GCw4H8Fm7YL_1xq_ALmlooA</recordid><startdate>198010</startdate><enddate>198010</enddate><creator>Ellis, K.O.</creator><creator>Wessels, F.L.</creator><creator>Burns, R.H.</creator><creator>Pong, S.F.</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198010</creationdate><title>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</title><author>Ellis, K.O. ; Wessels, F.L. ; Burns, R.H. ; Pong, S.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo</topic><topic>4-Dichlorobenzyl) - 3</topic><topic>6-tetrahydro-2(1H)-pyrimidone</topic><topic>6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity</topic><topic>Animals</topic><topic>Anti-Anxiety Agents</topic><topic>Antidepressive Agents</topic><topic>Brain Chemistry - drug effects</topic><topic>Cats</topic><topic>CNS activity-1-</topic><topic>CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo</topic><topic>evaluation of antidepressant and antianxiety activity</topic><topic>Female</topic><topic>Histamine H1 Antagonists</topic><topic>Humans</topic><topic>in vitro and in vivo</topic><topic>Lethal Dose 50</topic><topic>Male</topic><topic>Mice</topic><topic>Monoamine Oxidase Inhibitors</topic><topic>Neurotransmitter Agents - metabolism</topic><topic>Nictitating Membrane - drug effects</topic><topic>Parasympatholytics</topic><topic>Pentylenetetrazole - antagonists & inhibitors</topic><topic>Pyrimidinones - pharmacology</topic><topic>Rats</topic><topic>Stereotyped Behavior - drug effects</topic><topic>Tetrabenazine - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ellis, K.O.</creatorcontrib><creatorcontrib>Wessels, F.L.</creatorcontrib><creatorcontrib>Burns, R.H.</creatorcontrib><creatorcontrib>Pong, S.F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ellis, K.O.</au><au>Wessels, F.L.</au><au>Burns, R.H.</au><au>Pong, S.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1980-10</date><risdate>1980</risdate><volume>69</volume><issue>10</issue><spage>1198</spage><epage>1202</epage><pages>1198-1202</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><abstract>1-(3,4-Dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.</abstract><cop>Washington</cop><pub>Elsevier Inc</pub><pmid>6106711</pmid><doi>10.1002/jps.2600691021</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3549 |
ispartof | Journal of pharmaceutical sciences, 1980-10, Vol.69 (10), p.1198-1202 |
issn | 0022-3549 1520-6017 |
language | eng |
recordid | cdi_crossref_primary_10_1002_jps_2600691021 |
source | Wiley-Blackwell Journals |
subjects | 1-(3,4-Dichlorobenzyl) - 3,4,5,6-tetrahydro-2(1H)-pyrimidone—evaluation of antidepressant and antianxiety activity, in vitro and in vivo 4-Dichlorobenzyl) - 3 6-tetrahydro-2(1H)-pyrimidone 6-tetrahydro-2(1H)-pyrimidone-evaluation of antidepressant and antianxiety activity Animals Anti-Anxiety Agents Antidepressive Agents Brain Chemistry - drug effects Cats CNS activity-1- CNS activity—1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, evaluation of antidepressant and antianxiety activity, in vitro and in vivo evaluation of antidepressant and antianxiety activity Female Histamine H1 Antagonists Humans in vitro and in vivo Lethal Dose 50 Male Mice Monoamine Oxidase Inhibitors Neurotransmitter Agents - metabolism Nictitating Membrane - drug effects Parasympatholytics Pentylenetetrazole - antagonists & inhibitors Pyrimidinones - pharmacology Rats Stereotyped Behavior - drug effects Tetrabenazine - antagonists & inhibitors |
title | Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A12%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacology%20of%201-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone,%20a%20novel%20antidepressant%20compound%20with%20antianxiety%20activity&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Ellis,%20K.O.&rft.date=1980-10&rft.volume=69&rft.issue=10&rft.spage=1198&rft.epage=1202&rft.pages=1198-1202&rft.issn=0022-3549&rft.eissn=1520-6017&rft_id=info:doi/10.1002/jps.2600691021&rft_dat=%3Cwiley_cross%3EJPS2600691021%3C/wiley_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3421-4fcaa4059df75b34e88e384a876513cf8a29c314958b8c0348c0adaa2e0373c43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/6106711&rfr_iscdi=true |